EGFR-Mutated Lung Cancer: A Marked Response After Six Treatment Cycles

A 45-year-old gentleman came to see me with a persistent cough. A chest X-ray and CT scan revealed a mass in his right lung.

A biopsy confirmed lung cancer, and molecular testing identified an EGFR mutation. This information helped us develop a treatment plan tailored to the characteristics of his cancer.

Personalising Treatment for EGFR-Mutated Lung Cancer

Following clinical assessment, we started a combination of targeted therapy and chemotherapy. Our aim was to achieve substantial tumour shrinkage while carefully monitoring his tolerance to treatment.

Personalised cancer care considers the tumour’s molecular profile alongside the patient’s overall condition, treatment goals and preferences.

Before and After Six Treatment Cycles

The scan on the left shows the tumour before treatment, while the scan on the right shows the appearance after six treatment cycles.

The follow-up scan demonstrated a very good response, with marked tumour shrinkage.

These images illustrate the change at the selected scan level. We assess treatment response using the complete scan series together with symptoms, examination findings and other relevant investigations.

Treatment Tolerance Matters

He tolerated treatment well.

Alongside effectiveness, we pay close attention to side effects and quality of life. Regular monitoring helps us assess treatment tolerance and adjust care when necessary.

Good tolerance does not mean that treatment is free from side effects.

An Encouraging Response with Continued Follow-Up

This case highlights how molecular testing can help guide an individualised treatment approach.

The marked response after six cycles was encouraging. However, a good response does not necessarily mean a cure. Continued treatment assessment and follow-up remain important.